BRMS1 antibody
Principal name
BRMS1 antibody
Alternative names for BRMS1 antibody
Breast cancer metastasis-suppressor 1
Ncbi ID
NP_056214.1, 9606, NP_056214, BC003485, NM_134155, NM_001009605, NM_001024957
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB), ELISA (detection) (E(detection)), Paraffin Sections (P), Immunoprecipitation (IP)
Background of BRMS1 antibody
BRMS1 reduces the metastatic potential, but not the tumorogenicity, of human breast cancer and melanoma cell lines. The protein encoded by this gene localizes primarily to the nucleus and is a component of the mSin3a family of histone deacetylase complexes (HDAC). The protein contains two coiled-coil motifs and several imperfect leucine zipper motifs. Alternative splicing results in two transcript variants encoding different isoforms.
General readings
Meehan W.J., et al. (2004) J. Biol. Chem. 279:1562-1569.
Western Blot analysis of BRMS1 expression in transfected 293T cell line (H00025855-T01) by BRMS1 MaxPab polyclonal antibody.Lane 1: BRMS1 transfected lysate(27.06 KDa).Lane 2: Non-transfected lysate.
Western Blot analysis of BRMS1 expression in transfected 293T cell line (H00025855-T01) by BRMS1 MaxPab polyclonal antibody.Lane 1: BRMS1 transfected lysate(28.50 KDa).Lane 2: Non-transfected lysate.
BRMS1 monoclonal antibody (M01), clone 2D4-2G11. Western Blot analysis of BRMS1 expression in human liver.
Detection limit for recombinant GST tagged BRMS1 is approximately 3ng/ml as a capture antibody.
Detection limit for recombinant GST tagged BRMS1 is approximately 0.3ng/ml as a capture antibody.
Immunohistochemical analysis of BRMS1 staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
Western blot analysis of BRMS1 expression in HT29 (A); HeLa (B); MCF7 (C) whole cell lysates.
Western blot analysis of BRMS1 expression in HepG2 (A); HeLa (B); K562 (C) whole cell lysates.
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| C11729-1 | BRMS1 antibody |
||||||
 |
Rabbit | Aff - Purified | Hu, Ms, Rt | E, WB |
50 µg /
€230.00
|
||
| Assay Biotech | |||||||
| C11729-2 | BRMS1 antibody |
||||||
|
Rabbit | Aff - Purified | Hu, Ms, Rt | E, WB |
0.1 mg /
€330.00
|
||
| Assay Biotech | |||||||
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP303428 | BRMS1 (transcript variant 1) |
||||
| Recombinant protein of human breast cancer metastasis suppressor 1 (BRMS1), transcript variant 1 | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€438.00
|
|
| OriGene Technologies, Inc. | |||||
|
|||||
| AR51322PU-N | BRMS1 (1-246, T7 tag) |
||||
 |
Human | Purified | > 80 % by SDS - PAGE | E. coli |
0.1 mg /
€730.00
|
| Acris Antibodies GmbH | |||||
| AR51322PU-S | BRMS1 (1-246, T7 tag) |
||||
|
Human | Purified | > 80 % by SDS - PAGE | E. coli |
20 µg /
€300.00
|
| Acris Antibodies GmbH | |||||
Human Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| RC217422L2V | Lenti ORF particles, BRMS1 (mGFP-tagged) - Human breast cancer metastasis suppressor 1 (BRMS1), transcript variant 2, 200 uL, >10^7 TU/mL |
|
 |
200 µl /
€989.00
|
|
| OriGene Technologies, Inc. | ||
| RC217422L1V | Lenti ORF particles, BRMS1 (Myc-DDK tagged) - Human breast cancer metastasis suppressor 1 (BRMS1), transcript variant 2 , 200 uL, >10^7 TU/mL |
|
|
200 µl /
€886.00
|
|
| OriGene Technologies, Inc. | ||
Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR203076L2V | Lenti ORF particles, Brms1 (GFP-tagged) - Mouse breast cancer metastasis-suppressor 1 (Brms1), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€907.00
|
|
| OriGene Technologies, Inc. | ||
| MR200909L2V | Lenti ORF particles, Brms1 (GFP-tagged) - Mouse breast cancer metastasis-suppressor 1 (cDNA clone MGC:6927 IMAGE:2811430), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€814.00
|
|
| OriGene Technologies, Inc. | ||
| MR203076L1V | Lenti ORF particles, Brms1 (Myc-DDK-tagged) - Mouse breast cancer metastasis-suppressor 1 (Brms1), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€804.00
|
|
| OriGene Technologies, Inc. | ||
| MR200909L1V | Lenti ORF particles, Brms1 (Myc-DDK-tagged) - Mouse breast cancer metastasis-suppressor 1 (cDNA clone MGC:6927 IMAGE:2811430), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€721.00
|
|
| OriGene Technologies, Inc. | ||
Rat Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| RR200863L2V | Lenti ORF particles, Brms1 (GFP-tagged ORF) - Rat breast cancer metastasis-suppressor 1 (Brms1), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€907.00
|
|
| OriGene Technologies, Inc. | ||
| RR200863L1V | Lenti ORF particles, Brms1 (Myc-DDK-tagged ORF) - Rat breast cancer metastasis-suppressor 1 (Brms1), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€804.00
|
|
| OriGene Technologies, Inc. | ||
